EUVIMEDEUVIMED entdecken
Crossref

A44-14 National Trends in COPD Exacerbation Outcomes and Mortality, 2016-2021

S Mahapatra, A Memon, T Parvataneni, L Gulua

American Journal of Respiratory and Critical Care Medicine · 01.05.2026 · 212 (Supplement_1)

DOI: 10.1093/ajrccm/aamag162.1663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 15.05.2026. Verfasst von S Mahapatra und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a leading cause of hospitalization, mortality, and healthcare expenditure in the U.S. Despite evolving treatment approaches, nationally representative trends in outcomes and cost remain inadequately described.

Methods

We conducted a retrospective cross-sectional study using the HCUP-NIS database (2016-2021), including adults ≥40 years with a COPD diagnosis (ICD-10-CM: J41-J44). Exacerbations were defined by a primary diagnosis of acute respiratory failure (J96.x) with a secondary diagnosis of COPD, excluding admissions for heart failure (I50), pneumonia (J12-J18), and COVID-19 (U07.1). Outcomes included in-hospital mortality, use of mechanical ventilation (MV) and non-invasive ventilation (NIV), length of stay (LOS), and total hospital cost (CPI-adjusted to 2025 USD). Weighted analyses and multivariable regression models adjusted for demographics, comorbidities, and hospital characteristics.

Results

Among 2,664,123 COPD hospitalizations, 143,054 (5.4%) met criteria for AECOPD. Exacerbation admissions had significantly higher in-hospital mortality (4.7% vs. 2.2%), MV use (10.2% vs. 2.3%), and NIV use (22.6% vs. 3.0%) compared to non-exacerbation COPD (all p < 0.001). Mortality declined from 5.1% (2016) to 4.0% (2019), while NIV use rose steadily from 20.6% to 26.7%. On adjusted analysis, AECOPD independently predicted higher mortality (aOR 2.37, 95% CI 2.31-2.44) and MV use (aOR 5.10, 95% CI 5.00-5.20). Exacerbations were associated with slightly shorter LOS (−0.04 days, p = 0.009) and lower adjusted hospital costs (−$2,281, p < 0.001). Anemia (+$6,935), atrial fibrillation (+$2,162), and obesity (+$1,846) were major cost drivers.

Conclusions

Hospitalizations for AECOPD remain associated with high mortality and ventilation use, though outcomes have modestly improved. Rising use of NIV reflects a shift in management. The financial burden is substantial and driven by comorbid complexity. These findings underscore the need for better outpatient management and targeted interventions to reduce exacerbation-related hospitalizations. This abstract is funded by: none

Zitieren

APA

Mahapatra, S., Memon, A., Parvataneni, T., & Gulua, L. (2026). A44-14 National Trends in COPD Exacerbation Outcomes and Mortality, 2016-2021. American Journal of Respiratory and Critical Care Medicine, 212(Supplement_1). https://doi.org/10.1093/ajrccm/aamag162.1663

Vancouver

Mahapatra S, Memon A, Parvataneni T, Gulua L. A44-14 National Trends in COPD Exacerbation Outcomes and Mortality, 2016-2021. American Journal of Respiratory and Critical Care Medicine. 2026;212(Supplement_1). doi:10.1093/ajrccm/aamag162.1663

BibTeX
@article{Mahapatra2026,
  author = {Mahapatra, S and Memon, A and Parvataneni, T and Gulua, L},
  title = {A44-14 National Trends in COPD Exacerbation Outcomes and Mortality, 2016-2021},
  journal = {American Journal of Respiratory and Critical Care Medicine},
  year = {2026},
  volume = {212},
  number = {Supplement_1},
  doi = {10.1093/ajrccm/aamag162.1663}
}
Kostenlos starten →